RANBP1 and malignant colon neoplasm: Pharmacological inhibition of NPM1 was proved effective in restoring the sensitivity of vemurafenib-resistant colon cancer cells with the BRAFV600E mutation by mechanisms that include down-regulation of c-Myc expression and activity and consequent suppression of its transcriptional targets RanBP1 and phosphoserine phosphatase regulating centrosome duplication and serine biosynthesis, respectively.